Are US payers getting to grips with cost-effectiveness analysis?
Cost-effectiveness analysis (CEA) is widely used in many countries as part of the broader approach to the health technology assessment (HTA) decision process. It’s common in countries with a national or asocial health insurance system where there is a single payer making decisions for the larger population.
In the US, with the multi-payer system, the process is more complex and interpretation expertise of CEAs may vary, making CEA utilization among payers limited.
Xcenda’s FormularyDecision team conducted a study to assess the current use of CEAs by US decision-makers, the challenges that they currently face in using CEAs, and the ways in which these could resolved. Download our research below.